RxDoctor Payments Data

Ravinder Tikoo, MD

Neurology · North Bergen, NJNPI 1780713255

Payments from drug & device makers

$24,280in general payments, 2019–2025

Across 1,634 payments — averaging $14.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$4K
  • AbbVie$3K
  • EMD Serono, Inc.$3K
  • MDD US Operations, LLC$2K
  • Neurocrine Biosciences, Inc.$1K
  • Pfizer$1K
  • plus $11K from 54 others

What the payments were for

  • Speaking & faculty fees$930%
  • Food & beverage$23,46697%
  • Education$7213%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.309$3,835
AbbVie(2 entities)195$3,164
EMD Serono, Inc.76$2,617
MDD US Operations, LLC105$1,606
Neurocrine Biosciences, Inc.71$1,105
Pfizer95$1,023
Lundbeck LLC64$954
Novartis60$742
Acadia Pharmaceuticals Inc36$691
Takeda Pharmaceuticals U.S.A., Inc.61$672
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)48$660
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC42$611
Lilly USA, LLC50$587
Avanir Pharmaceuticals, Inc.43$563
Sunovion Pharmaceuticals Inc.45$521
Axsome Therapeutics, Inc.20$435
SK Life Science, Inc.29$432
Daiichi Sankyo Inc.74$430
Biohaven Pharmaceutical Holding Company Ltd.23$313
Bristol Myers Squibb15$307
Eisai Inc.12$276
Amneal Pharmaceuticals LLC2$250
AstraZeneca(2 entities)16$241
Kowa Pharmaceuticals America, Inc.13$184
Collegium Pharmaceutical, Inc.13$172
Otsuka America Pharmaceutical, Inc.9$152
Biogen8$131
Scilex Pharmaceuticals Inc.7$112
Alnylam Pharmaceuticals Inc.3$105
Amgen(2 entities)7$103
Sumitomo Pharma America, Inc.8$92
UCB, Inc.5$90
Redhill Biopharma Inc.6$85
E.r. Squibb & Sons, L.L.C.5$75
Nevro Corp.1$70
Idorsia Pharmaceuticals US Inc4$63
Acorda Therapeutics, Inc4$59
Sanofi4$57
Livanova USA, Inc.3$50
Impel Pharmaceuticals Inc.3$49
Supernus Pharmaceuticals, Inc.3$46
TG Therapeutics, Inc.2$41
Biohaven Pharmaceuticals, Inc.3$38
Biodelivery Sciences International, Inc.3$38
Abbott2$35
Novo Nordisk2$35
Vanda Pharmaceuticals Inc.2$33
Neurelis, Inc.2$29
Johnson & Johnson2$28
Greenwich Biosciences, Inc.2$27
Currax Pharmaceuticals LLC2$27
Shionogi Inc2$26
Ossur Americas, Inc.1$26
G Medical Diagnostic Services, Inc.2$25
Mallinckrodt Enterprises LLC2$23
Argenx US, Inc.1$21
ANI Pharmaceuticals, Inc.1$20
Almatica Pharma LLC1$14
Merck1$14
Vertical Pharmaceuticals, LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,280 in reported general payments places this provider in the 75th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$348,246
Medicare patients
315
Services billed
2,573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate43$214,692
AustedoDeutetrabenazine19$161,891
Nurtec OdtRimegepant Sulfate54$99,115
UbrelvyUbrogepant63$84,232
NuedextaDextromethorphan Hbr/Quinidine28$37,221
Emgality PenGalcanezumab-Gnlm41$32,337
TrintellixVortioxetine Hydrobromide56$26,063
QuliptaAtogepant12$19,323
BriviactBrivaracetam12$17,076
BelsomraSuvorexant15$6,600
Acetaminophen-CodeineAcetaminophen With Codeine235$4,081
Lidocaine45$3,235
Gabapentin221$2,035
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen125$2,014
Carbidopa-LevodopaCarbidopa/Levodopa159$1,888

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$691$214,69243 claims
Teva Pharmaceuticals USA, Inc.Austedo$3,835$161,89119 claims
AbbVieUbrelvy, Qulipta$3,164$103,55575 claims
PfizerNurtec Odt$1,023$99,11554 claims
Avanir Pharmaceuticals, Inc.Nuedexta$563$37,22128 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$672$26,06356 claims
UCB, Inc.Briviact$90$17,07612 claims
MerckBelsomra$14$6,60015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 521 neurology providers in New Jersey.

Other neurology in North Bergen

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →